15 Octobre 2025
Rare Disease
...
25 Février 2025
Rare Disease
...
-
22 Juillet 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. ...
-
01 Juillet 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and o...